Alnuctamab
- Generic Name
- Alnuctamab
- Drug Type
- Biotech
- CAS Number
- 2296827-07-9
- Unique Ingredient Identifier
- 7OSV6M6T4D
A Study to Evaluate Efficacy and Safety of Alnuctamab Compared to Standard of Care Regimens in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)
- Conditions
- Multiple Myeloma
- Interventions
- First Posted Date
- 2024-01-31
- Last Posted Date
- 2024-05-31
- Lead Sponsor
- Celgene
- Registration Number
- NCT06232707
- Locations
- 🇺🇸
Local Institution - 0088, Los Angeles, California, United States
🇺🇸Local Institution - 0324, Baltimore, Maryland, United States
🇦🇺Local Institution - 0022, Waratah, New South Wales, Australia
A Study to Evaluate Alnuctamab in Combination With Mezigdomide in Participants With Relapsed and/or Refractory Multiple Myeloma
- Conditions
- Multiple Myeloma
- Interventions
- First Posted Date
- 2023-12-11
- Last Posted Date
- 2025-04-04
- Lead Sponsor
- Celgene
- Target Recruit Count
- 156
- Registration Number
- NCT06163898
- Locations
- 🇺🇸
Local Institution - 0035, New Haven, Connecticut, United States
🇺🇸Local Institution - 0018, New York, New York, United States
🇺🇸Local Institution - 0033, Birmingham, Alabama, United States
A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of BMS-986393 in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma
- Conditions
- Multiple Myeloma
- Interventions
- First Posted Date
- 2023-11-08
- Last Posted Date
- 2025-04-30
- Lead Sponsor
- Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
- Target Recruit Count
- 111
- Registration Number
- NCT06121843
- Locations
- 🇺🇸
Mayo Clinic in Arizona - Phoenix, Phoenix, Arizona, United States
🇺🇸Mayo Clinic in Florida, Jacksonville, Florida, United States
🇺🇸Mayo Clinic in Rochester, Minnesota, Rochester, Minnesota, United States
Study of CC-93269, a BCMA x CD3 T Cell Engaging Antibody, in Participants With Relapsed and Refractory Multiple Myeloma
- First Posted Date
- 2018-04-03
- Last Posted Date
- 2025-04-17
- Lead Sponsor
- Celgene
- Target Recruit Count
- 183
- Registration Number
- NCT03486067
- Locations
- 🇺🇸
Local Institution - 106, Atlanta, Georgia, United States
🇺🇸Local Institution - 111, Boston, Massachusetts, United States
🇺🇸Local Institution - 101, Seattle, Washington, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.